Maureen E. Thyne Discusses Ruxolitinib's Impact on Myelofibrosis

Video

Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.

Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.

Since its approval in December 2011, ruxolitinib has improved not only side effects, but also overall survival and quality of life. Five-year data is expected to be reported later this year.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Image of a woman with a blue background
5 experts in this video
5 experts in this video
Image of a man in scrubs with short hair and glasses
Photo of a woman with brown hair and bangs, surrounded by a blue border
Related Content